Targeting intraocular neovascularization and edema - One drop at a time

New England Journal of Medicine

Volumn 359, Issue 9, 2008, Pages 967-969

  Aiello, Lloyd Paul ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ARTICLE; EDEMA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA BLOOD VESSEL OCCLUSION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; VISUAL IMPAIRMENT;

EID: 50449090755     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr0804551     Document Type: Article

References (5)

1. Scheppke L, Aguilar E, Gariano RF, et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 2008;118:2337-46.
2. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008;216:29-37.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
4. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-92.
5. Gao BB, Clermont A, Rook S, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007;13:181-8.